Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Italy ETF (EWI) vs Cassava Sciences Inc (FLNA) Price & Performance

Ishares Msci Italy ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Italy ETF vs Cassava Sciences Inc — how do they compare? Ishares Msci Italy ETF trades at $63.25, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Ishares Msci Italy ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

EWIFLNA
Sector
Broad Market / FactorHealth
52-Week High
$63.35$4.64
52-Week Low
$50.31$0.87
Market Cap
$47.75M
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Italy ETF

EWI, a US-listed stock, trades at $63.35, up 0.3% on the day, with technical indicators showing a bullish moving average trend but overbought oscillators. The stock recently hit a 52-week high, reflecting strong momentum. A dividend of $1.17 is scheduled for payment in June 2026, offering income potential. Recent news highlights European market strength and ECB policy impacts, which may influence EWI's performance given its European exposure.

The outlook for EWI is cautiously optimistic, driven by technical strength and positive European equity trends. Risks include potential ECB rate hikes and geopolitical tensions affecting energy costs. Analyst sentiment is mixed, with the stock near highs suggesting limited upside without new catalysts. Investors should weigh technical overbought signals against fundamental growth prospects.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

About Ishares Msci Italy ETF

EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.

Read more on EWI

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA